We hypothesize that biofield therapy will alter the proliferation of HCC and PDAC by targeting the cell signaling pathway and stemness of tumor cells in the tumor and tumor microenvironment. Human breast cancer MDA-MB-231 cells and mouse lung carcinoma LLC cells will be used as positive control and explored further as appropriate. We will pursue the following aims to test these hypotheses: 1. To determine the effect of biofield therapy in the proliferation of gastrointestinal carcinoma, especially HCC and PDAC, LLC, and MDA-MB-231cells and their relevant molecular mechanisms. 2. To determine the antitumor efficacy of biofield therapy in orthotopic pancreatic mouse model and spontaneous mouse HCC model (models where the cancer grows within the respective organs). 3. To examine if biofield therapy has a direct impact on mouse brain function in real-time to help in determining the mechanisms of biofield therapy. 4. To evaluate neural correlates in healer and healing target. 5. To assess ability to block the healing effect with electromagnetically blocking Faraday cage. 6. To evaluate the effect of a sound recording of healer. 7. To evaluate the effect of distance healing in vitro.